Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by DIPEN MAHESHBHAI MARU and WAYNE L HOFSTETTER.
DIPEN MAHESHBHAI MARU
Connection Strength
6.447
WAYNE L HOFSTETTER
  1. ANPEP/CD13 Expression as a Marker of?Lymphovascular Invasion and Survival in?Esophageal Adenocarcinoma. Ann Thorac Surg. 2024 Jul; 118(1):241-251.
    View in: PubMed
    Score: 0.924
  2. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008 Sep; 32(9):1404-11.
    View in: PubMed
    Score: 0.325
  3. Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma. Ann Thorac Surg. 2024 Feb; 117(2):320-326.
    View in: PubMed
    Score: 0.224
  4. Prolonged neutrophilia is associated with worse outcomes after Esophagectomy. Dis Esophagus. 2022 Apr 19; 35(4).
    View in: PubMed
    Score: 0.209
  5. Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. Ann Thorac Surg. 2021 04; 111(4):1133-1140.
    View in: PubMed
    Score: 0.186
  6. Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus. 2020 Mar 16; 33(3).
    View in: PubMed
    Score: 0.181
  7. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech. 2019 12 17; 12(12).
    View in: PubMed
    Score: 0.178
  8. Should endoscopic mucosal resection be attempted for cT2N0 esophageal cancer? Dis Esophagus. 2019 Dec 13; 32(10):1-6.
    View in: PubMed
    Score: 0.177
  9. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. Ther Adv Med Oncol. 2019; 11:1758835919864850.
    View in: PubMed
    Score: 0.173
  10. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. Oncotarget. 2019 Jul 23; 10(45):4703-4718.
    View in: PubMed
    Score: 0.173
  11. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. Ann Thorac Surg. 2019 09; 108(3):845-851.
    View in: PubMed
    Score: 0.170
  12. Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2018 07; 156(1):406-413.e3.
    View in: PubMed
    Score: 0.157
  13. HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells. Ann Thorac Surg. 2018 Feb; 105(2):363-370.
    View in: PubMed
    Score: 0.154
  14. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017 Apr 25; 8(17):28696-28710.
    View in: PubMed
    Score: 0.148
  15. Early clinical esophageal adenocarcinoma (cT1): Utility of CT in regional nodal metastasis detection and can the clinical accuracy be improved? Eur J Radiol. 2017 Mar; 88:56-60.
    View in: PubMed
    Score: 0.145
  16. Endoscopic Ultrasound Estimates for Tumor Depth at the Gastroesophageal Junction Are Inaccurate: Implications for the Liberal Use of Endoscopic Resection. Ann Thorac Surg. 2015 Nov; 100(5):1812-6.
    View in: PubMed
    Score: 0.131
  17. Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. Ann Thorac Surg. 2014 Sep; 98(3):1064-71.
    View in: PubMed
    Score: 0.122
  18. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg. 2012 Feb; 143(2):412-20.
    View in: PubMed
    Score: 0.102
  19. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg. 2012 Jan; 93(1):207-12; discussion 212-3.
    View in: PubMed
    Score: 0.100
  20. Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma. Am J Surg Pathol. 2011 Jul; 35(7):1045-53.
    View in: PubMed
    Score: 0.099
  21. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010 Sep; 90(3):884-90; discussion 890-1.
    View in: PubMed
    Score: 0.093
  22. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Mod Pathol. 2009 Dec; 22(12):1612-21.
    View in: PubMed
    Score: 0.087
  23. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer. 2009 Apr 01; 115(7):1576-85.
    View in: PubMed
    Score: 0.084
  24. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol. 2009 May; 174(5):1940-8.
    View in: PubMed
    Score: 0.084
  25. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg. 2007 Aug; 84(2):365-73; discussion 374-5.
    View in: PubMed
    Score: 0.075
  26. Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. Ann Thorac Surg. 2022 12; 114(6):2032-2040.
    View in: PubMed
    Score: 0.051
  27. Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg. 2021 04 01; 273(4):751-757.
    View in: PubMed
    Score: 0.049
  28. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. J Thorac Cardiovasc Surg. 2021 Nov; 162(5):1404-1412.e2.
    View in: PubMed
    Score: 0.047
  29. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer. 2011 Jan 01; 117(1):63-9.
    View in: PubMed
    Score: 0.047
  30. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. 2020 08; 272(2):311-318.
    View in: PubMed
    Score: 0.046
  31. Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. Gastric Cancer. 2020 09; 23(5):904-912.
    View in: PubMed
    Score: 0.046
  32. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. Medicine (Baltimore). 2020 Feb; 99(9):e19295.
    View in: PubMed
    Score: 0.045
  33. Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and Outcomes. Ann Surg. 2019 04; 269(4):663-670.
    View in: PubMed
    Score: 0.042
  34. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg. 2018 08; 268(2):289-295.
    View in: PubMed
    Score: 0.040
  35. Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology. 2018; 95(2):81-90.
    View in: PubMed
    Score: 0.040
  36. Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology. 2018; 94(6):345-353.
    View in: PubMed
    Score: 0.040
  37. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma. Ann Surg Oncol. 2018 Jun; 25(6):1598-1607.
    View in: PubMed
    Score: 0.039
  38. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Target Oncol. 2018 02; 13(1):99-106.
    View in: PubMed
    Score: 0.039
  39. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. Br J Cancer. 2018 02 06; 118(3):331-337.
    View in: PubMed
    Score: 0.039
  40. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113.
    View in: PubMed
    Score: 0.038
  41. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer. 2017 Aug 22; 117(5):648-655.
    View in: PubMed
    Score: 0.038
  42. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology. 2017; 93(4):243-248.
    View in: PubMed
    Score: 0.037
  43. Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. Med Oncol. 2017 Aug; 34(8):135.
    View in: PubMed
    Score: 0.037
  44. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017 08; 124(2):318-324.
    View in: PubMed
    Score: 0.037
  45. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):667-676.
    View in: PubMed
    Score: 0.037
  46. Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. Oncotarget. 2017 Oct 03; 8(45):79356-79365.
    View in: PubMed
    Score: 0.037
  47. Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):316-324.
    View in: PubMed
    Score: 0.037
  48. Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. Oncology. 2016; 91(1):55-60.
    View in: PubMed
    Score: 0.034
  49. A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. J Natl Compr Canc Netw. 2016 02; 14(2):173-9.
    View in: PubMed
    Score: 0.034
  50. Can the Risk of Lymph Node Metastases Be Gauged in Endoscopically Resected Submucosal Esophageal Adenocarcinomas? A Multi-Center Study. J Gastrointest Surg. 2016 Jan; 20(1):6-12; discussion 12.
    View in: PubMed
    Score: 0.033
  51. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer. 2015 Nov; 51(17):2545-52.
    View in: PubMed
    Score: 0.033
  52. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology. 2015; 88(6):332-6.
    View in: PubMed
    Score: 0.032
  53. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol. 2015 Feb; 6(1):45-52.
    View in: PubMed
    Score: 0.032
  54. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014 Oct 20; 32(30):3400-5.
    View in: PubMed
    Score: 0.031
  55. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014 Aug; 12(8):1139-44.
    View in: PubMed
    Score: 0.031
  56. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014; 86(5-6):336-9.
    View in: PubMed
    Score: 0.030
  57. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res. 2014 Aug 01; 74(15):4170-82.
    View in: PubMed
    Score: 0.030
  58. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014 Feb; 8(1):142-9.
    View in: PubMed
    Score: 0.029
  59. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013 Dec 01; 31(34):4306-10.
    View in: PubMed
    Score: 0.029
  60. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013; 85(4):204-7.
    View in: PubMed
    Score: 0.029
  61. The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. Ann Surg. 2013 Sep; 258(3):500-7.
    View in: PubMed
    Score: 0.029
  62. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol. 2013 Nov; 24(11):2854-9.
    View in: PubMed
    Score: 0.029
  63. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov; 24(11):2844-9.
    View in: PubMed
    Score: 0.029
  64. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology. 2013; 85(2):95-9.
    View in: PubMed
    Score: 0.028
  65. Loss of TGF-? adaptor ?2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. Cancer Res. 2013 Apr 01; 73(7):2159-69.
    View in: PubMed
    Score: 0.028
  66. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2013 May; 24(5):1262-6.
    View in: PubMed
    Score: 0.027
  67. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4.
    View in: PubMed
    Score: 0.027
  68. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg. 2012 Oct; 94(4):1126-32; discussion 1132-3.
    View in: PubMed
    Score: 0.027
  69. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404.
    View in: PubMed
    Score: 0.027
  70. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012 Oct; 23(10):2638-2642.
    View in: PubMed
    Score: 0.027
  71. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012; 82(2):108-13.
    View in: PubMed
    Score: 0.026
  72. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus. 2012 Sep-Oct; 25(7):614-22.
    View in: PubMed
    Score: 0.025
  73. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011 Nov 01; 117(21):4823-33.
    View in: PubMed
    Score: 0.024
  74. Dysfunctional transforming growth factor-? signaling with constitutively active Notch signaling in Barrett's esophageal adenocarcinoma. Cancer. 2011 Aug 15; 117(16):3691-702.
    View in: PubMed
    Score: 0.024
  75. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer. 2011 Mar 01; 117(5):925-30.
    View in: PubMed
    Score: 0.024
  76. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. 2010 Sep; 90(3):892-8; discussion 898-9.
    View in: PubMed
    Score: 0.023
  77. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01; 116(7):1656-63.
    View in: PubMed
    Score: 0.023
  78. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009 Nov 15; 115(22):5184-92.
    View in: PubMed
    Score: 0.022
  79. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009 Oct; 138(4):831-6.
    View in: PubMed
    Score: 0.021
  80. Esophageal tumor length is independently associated with long-term survival. Cancer. 2009 Feb 01; 115(3):508-16.
    View in: PubMed
    Score: 0.021
  81. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer. 2009 Feb 01; 115(3):624-30.
    View in: PubMed
    Score: 0.021
  82. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus. 2009; 22(2):127-32.
    View in: PubMed
    Score: 0.021
  83. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus. 2009; 22(1):32-41.
    View in: PubMed
    Score: 0.021
  84. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer. 2008 Sep 15; 113(6):1302-8.
    View in: PubMed
    Score: 0.020
  85. Optical EMR: confocal endomicroscopy-targeted EMR of focal high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc. 2009 Jan; 69(1):170-2.
    View in: PubMed
    Score: 0.020
  86. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer. 2008 Mar 01; 112(5):1020-7.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.